|
Kidney Diseases
|
0.040 |
GeneticVariation
|
group |
BEFREE |
In humans, inactivating mutations in GLUT2 cause Fanconi-Bickel syndrome, which is characterised by hepatomegaly and kidney disease; defects in insulin secretion are rare in adult patients, but GLUT2 mutations cause transient neonatal diabetes.
|
25421524 |
2015 |
|
Kidney Diseases
|
0.040 |
GeneticVariation
|
group |
BEFREE |
FBS is caused by mutations in the glucose and galactose transporter gene SLC2A2 (HGNC ID11006) [Santeret al.(1997); Nat Genet 17: 324–326] and is characterized by hepatic glycogen accumulation with hepatomegaly, fasting hypoglycemia, short stature, impaired glucose tolerance, hyperlipidemia, and tubular nephropathy.
|
21271664 |
2011 |
|
Kidney Diseases
|
0.040 |
GeneticVariation
|
group |
BEFREE |
The T-allele of SLC2A2_16459CT was associated with a decreased risk of diabetic nephropathy (odds ratio 0.79 [95% CI 0.66-0.96], P = 0.016), whereas the T-allele of KNG_7965CT and the A-allele of ADIPOQ_prom2GA were associated with increased risk of nephropathy (1.17 [1.03-1.32], P = 0.016; 1.46 [1.11-1.93], P = 0.006, respectively).
|
17065357 |
2006 |
|
Kidney Diseases
|
0.040 |
GeneticVariation
|
group |
BEFREE |
This system enables testing of putative modulators of GLUT2 translocation, which are potential drugs for conditions of impaired glucose homeostasis and associated nephropathy.
|
29218530 |
2018 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
IL12A was amplified as single gene in three tumors and in a subline of the DU145 cell line, SLC2A2 in one tumor.
|
11074522 |
2000 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Northern blot analysis of RNA obtained from the tumor showed a high abundance of the low Km glucose transporter GLUT1 but no transcript for the high Km glucose transporter GLUT2.
|
9251924 |
1997 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Glut-1 and Glut-4 mRNA levels in IL-1beta mice were similar to mRNA levels in pair-fed mice bearing nonsecreting tumor. mRNA level of Glut-2, the major Glut of the liver, was down-regulated by IL-1beta.
|
15297440 |
2004 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
The genes which were selected for their known function and their potential involvement in tumour development included the genes for ribosomal protein L22 (RPL22), butyrylcholinesterase (BCHE), glucose transporter 2 (SLC2A2), transferrin receptor (TFRC), thrombopoietin (THPO) and the phosphatidylinositol-3 kinase catalytic alpha polypeptide (PIK3CA).
|
10492640 |
1999 |
|
Cardiovascular Diseases
|
0.030 |
GeneticVariation
|
group |
BEFREE |
Genetic variant SLC2A2 [corrected] Is associated with risk of cardiovascular disease – assessing the individual and cumulative effect of 46 type 2 diabetes related genetic variants.
|
23185617 |
2012 |
|
Cardiovascular Diseases
|
0.030 |
GeneticVariation
|
group |
BEFREE |
The association between SLC2A2 rs8192675 and high-density lipoproteins suggests the polymorphism may play a role in influencing high-density lipoproteins and thus metabolic risk of cardiovascular disease.
|
23341889 |
2013 |
|
Cardiovascular Diseases
|
0.030 |
GeneticVariation
|
group |
BEFREE |
Genome-wide association studies have reported that GLUT2 variants increase the risks of fasting hyperglycaemia, transition to type 2 diabetes, hypercholesterolaemia and cardiovascular diseases.
|
25421524 |
2015 |
|
Carcinoma
|
0.020 |
Biomarker
|
group |
BEFREE |
Together, our reverse chromosome painting data and our PCR analysis indicate gene amplification at 3q26 in 40% of all squamous cell lung carcinomas with BCHE and SLC2A2 as possible target genes of the amplification unit in squamous cell lung carcinoma.
|
9187134 |
1997 |
|
Carcinoma
|
0.020 |
Biomarker
|
group |
BEFREE |
Recently, we reported amplifications on chromosomal bands 3q26.1-q26.3 with the genes BCHE and SLC2A2 amplified in 40% of squamous cell lung carcinomas.
|
10853020 |
2000 |
|
Hypertensive disease
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Increased adipose cell size, hepatic fat deposition, malondialdehyde (MDA) content and NEFA level, down-regulation of IRS1, IRS2, PI3K, Akt, p-Akt, Glut2 and PGC1ɑ expression concomitant with up-regulation of mTOR, GSK3β, TNF-ɑ, FOXO1, p-mTOR and p-p70S6K expression in the liver tissue, as well as hypertension and left ventricular diastolic dysfunction were observed in HFC-fed minipigs.
|
30686655 |
2019 |
|
Hypertensive disease
|
0.020 |
Biomarker
|
group |
BEFREE |
GLUT5- and GLUT2-mediated fructose effects on intestinal electrolyte transporters, hepatic uric acid metabolism, as well as renal and cardiomyocyte function, may play a role in fructose-induced hypertension.
|
23129794 |
2013 |
|
Malignant Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
GLUT2 protein expression was significantly reduced in human HCC as compared to normal liver tissue and its expression in HCC was inversely associated to malignancy (p < 0.001).
|
31407220 |
2019 |
|
Metabolic Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
The contribution of GLUT2 to human metabolic diseases previously appeared modest.
|
19223655 |
2009 |
|
Neural Tube Defects
|
0.010 |
Biomarker
|
group |
BEFREE |
Presence of wild-type facilitated glucose transporter, Glut2, in mouse embryos has been shown to increase risk for NTDs in hyperglycemic pregnancy.
|
25776730 |
2015 |
|
Virus Diseases
|
0.010 |
GeneticVariation
|
group |
BEFREE |
We report a patient harbouring a homozygous mutation of SLC2A2 who presented a dramatic exacerbation of metabolic acidosis in the context of a viral infection, owing to both ketosis and major urinary bicarbonate loss.
|
25165176 |
2014 |
|
B-Cell Lymphomas
|
0.010 |
Biomarker
|
group |
BEFREE |
The effect of FFA on sterol regulatory element-binding protein (SREBP)-1c lipogenic pathway, and expression of genes involved in beta-cell functions, including AMPK (AMP-activated protein kinase), UCP-2 (uncoupling protein-2), IRS-2 (insulin receptor substrate-2), PDX-1 (pancreatic duodenal homeobox-1), GLUT-2 (glucose transporter-2) and B cell lymphoma/leukaemia-2 (Bcl-2) were investigated.
|
19758361 |
2010 |
|
Renal glomerular disease
|
0.010 |
Biomarker
|
group |
BEFREE |
Elevated levels of glucose and/or its metabolites in renal tubular cells may be necessary but not sufficient for the development of both the renal tubulopathy and diabetic-like glomerular disease in GLUT2 deficiency.
|
16288895 |
2005 |
|
Glucose Metabolism Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
These findings clearly indicate that SNAAP has significant potency in radiation-induced glucose metabolism disorder through modulating the JNK pathway in the liver as well as the PDX1/GLUT2 in the pancreas.
|
31132438 |
2019 |
|
Primary malignant neoplasm
|
0.010 |
AlteredExpression
|
group |
BEFREE |
GLUT2 protein expression was significantly reduced in human HCC as compared to normal liver tissue and its expression in HCC was inversely associated to malignancy (p < 0.001).
|
31407220 |
2019 |
|
Short stature
|
0.300 |
Biomarker
|
phenotype |
GENOMICS_ENGLAND |
Incidence, genetics, and clinical phenotype of permanent neonatal diabetes mellitus in northwest Saudi Arabia.
|
22060631 |
2012 |
|
Short Stature, CTCAE
|
0.300 |
Biomarker
|
phenotype |
GENOMICS_ENGLAND |
Incidence, genetics, and clinical phenotype of permanent neonatal diabetes mellitus in northwest Saudi Arabia.
|
22060631 |
2012 |